Eye Affecting Patents (Class 514/20.8)
-
Publication number: 20140294877Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: March 4, 2014Publication date: October 2, 2014Applicant: CUREVAC GMBHInventors: Patrick BAUMHOF, Thomas SCHLAKE
-
Patent number: 8841259Abstract: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.Type: GrantFiled: February 16, 2006Date of Patent: September 23, 2014Assignee: Joslin Diabetes CenterInventors: Edward P. Feener, Lloyd P. Aiello
-
Publication number: 20140274910Abstract: The present invention relates to methods of treating dry eye using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: Mimetogen Pharmaceuticals, Inc.Inventors: Garth CUMBERLIDGE, Karen MEEROVITCH, Teresa LAMA
-
Patent number: 8835571Abstract: A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.Type: GrantFiled: April 19, 2013Date of Patent: September 16, 2014Assignee: Sucampo AGInventors: Ryuji Ueno, Peter Lichtlen, Robert Gurny, Michael Möller
-
Publication number: 20140256625Abstract: The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis.Type: ApplicationFiled: July 9, 2012Publication date: September 11, 2014Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Charlotte Hauser, Anupama Lakshmanan
-
Publication number: 20140249072Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: ApplicationFiled: May 4, 2012Publication date: September 4, 2014Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Patent number: 8821874Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: July 22, 2013Date of Patent: September 2, 2014Assignee: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
-
Publication number: 20140235553Abstract: Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.Type: ApplicationFiled: March 30, 2012Publication date: August 21, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corprateInventors: Jonathan Mark Petrash, Niklaus Mueller
-
Publication number: 20140235554Abstract: An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one embodiment, the silk protein may be fibroin. A method of treating an eye having an ocular surface is also described. The method comprises providing an ophthalmic composition comprising an aqueous solution including an effective amount of silk protein, and administering the ophthalmic composition topically to the ocular surface.Type: ApplicationFiled: February 12, 2014Publication date: August 21, 2014Inventors: Brian Lawrence, Jon St. Germain
-
Patent number: 8802129Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.Type: GrantFiled: July 19, 2013Date of Patent: August 12, 2014Assignee: Allergan, Inc.Inventors: Scott M. Whitcup, David A. Weber
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8802075Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.Type: GrantFiled: February 18, 2010Date of Patent: August 12, 2014Assignee: Eyeon Particle Sciences LLCInventors: Eugene R. Cooper, David M. Kleinman, Andrew Loxley, Mark Mitchnick
-
Publication number: 20140221295Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: March 12, 2014Publication date: August 7, 2014Applicant: Molecular Partners AGInventors: Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
-
Patent number: 8796223Abstract: The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.Type: GrantFiled: January 8, 2013Date of Patent: August 5, 2014Assignee: The Regents of The University of MichiganInventor: David Noam Zacks
-
Patent number: 8785395Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: May 3, 2011Date of Patent: July 22, 2014Assignees: The Texas A & M University System, Temple Therapeutics, Inc.Inventors: Darwin J. Prockop, Joo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz
-
Patent number: 8778881Abstract: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: GrantFiled: March 1, 2012Date of Patent: July 15, 2014Assignee: Ferring B.V.Inventors: Kazimierz Wisniewski, Claudio Schteingart, Regent LaPorte, Robert Felix Galyean, Pierre J.M. Riviere
-
Patent number: 8778886Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.Type: GrantFiled: February 26, 2010Date of Patent: July 15, 2014Assignee: Tufts UniversityInventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read
-
Publication number: 20140194343Abstract: [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. [Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.Type: ApplicationFiled: May 9, 2012Publication date: July 10, 2014Applicant: THE UNIVERSITY OF TOKYOInventors: Yoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
-
Publication number: 20140193466Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.Type: ApplicationFiled: June 7, 2012Publication date: July 10, 2014Applicant: CORNELL UNIVERSITYInventors: Brian D Lawrence, Alejandro Navas, Mark I. Rosenblatt
-
Publication number: 20140194359Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.Type: ApplicationFiled: January 15, 2014Publication date: July 10, 2014Applicant: Alcon Research, Ltd.Inventors: Ying Yu, Jon E. Chatterton
-
Publication number: 20140186350Abstract: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.Type: ApplicationFiled: December 17, 2013Publication date: July 3, 2014Inventors: Joy GHOSH, Michael ROGUSKA, Andrew Anh NGUYEN, Thomas PIETZONKA, Stephen POOR, Matthais MACHACEK, Chad BIGELOW
-
Publication number: 20140187498Abstract: Compositions and methods for diagnosing, predicting risk of, and/or treating diabetic retinopathy and/or diabetic nephropathy.Type: ApplicationFiled: December 6, 2011Publication date: July 3, 2014Inventors: George L. King, Hillary A. Keenan
-
Publication number: 20140187497Abstract: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders.Type: ApplicationFiled: November 22, 2013Publication date: July 3, 2014Applicants: Louisiana State University Agricultural and Mechanical College, ATON PHARMA, INC.Inventors: Jean Theresa JACOB, Kevin John HALLORAN, Yuri MCKEE
-
Publication number: 20140187496Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.Type: ApplicationFiled: May 17, 2012Publication date: July 3, 2014Inventor: Pierre BITOUN
-
Publication number: 20140178309Abstract: A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy.Type: ApplicationFiled: January 17, 2014Publication date: June 26, 2014Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Jayakrishna AMBATI, Valeria TARALLO
-
Publication number: 20140179621Abstract: This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.Type: ApplicationFiled: August 9, 2013Publication date: June 26, 2014Applicant: Ophthotech CorporationInventors: Samir Patel, Harvey Masonson
-
Publication number: 20140178407Abstract: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.Type: ApplicationFiled: July 23, 2013Publication date: June 26, 2014Applicant: MASSACHUSETTS EYE AND EAR INFIRMARYInventors: Evangelos S. Gragoudas, Vasiliki Poulaki, Joan W. Miller
-
Publication number: 20140171376Abstract: A light-sensitive chimeric protein comprising domains from at least two members of the G-protein-coupled-receptor (GPCR) protein super family, which are fused to yield a light-sensitive GPCR chimera capable of coupling a light signal to the signaling cascade of the metabotropic glutamate receptor 6 (mGluR6) is provided for medical therapy and for the manufacture of medicaments for improving vision, in particular for treating loss of vision resulting from retinal photoreceptor degeneration. A first of the at least two GPCR family members contributes domains which mediate the light-sensitivity to the chimeric light-sensitive GPCR protein. This first member belongs to the family of light-sensitive GPCR proteins also called photopigments, and in some embodiments this light-sensitive GPCR protein is melanopsin, in particular human melanopsin.Type: ApplicationFiled: June 22, 2012Publication date: June 19, 2014Inventors: Michiel Van Wyk, Sonja Kleinlogel
-
Patent number: 8754048Abstract: Disclosed is a Volvox carteri-derived light-receiving channel rhodopsin with an improved expression efficiency on a cell membrane. Specifically disclosed is a modified Volvox carteri-derived light-receiving channel rhodopsin protein. The protein is modified to contain an N-terminal region of Chlamydomonas reinhardtii-derived channel rhodopsin-1 at the N-terminal of the Volvox carteri-derived light-receiving channel rhodopsin protein, wherein the N-terminal region is involved in cell membrane-localized expression and contains no transmembrane domain of the Chlamydomonas reinhardtii-derived channel rhodopsin-1.Type: GrantFiled: August 10, 2010Date of Patent: June 17, 2014Assignee: Tohoku UniversityInventors: Hiroshi Tomita, Eriko Sugano
-
Patent number: 8754037Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: GrantFiled: December 21, 2011Date of Patent: June 17, 2014Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20140162944Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicant: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Publication number: 20140140992Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.Type: ApplicationFiled: June 11, 2012Publication date: May 22, 2014Applicants: ICON BIOSCIENCE, INC., RAMSCOR, INC.Inventors: Vernon G. Wong, Louis L. Wood, Glenn T. Huang
-
Patent number: 8729010Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.Type: GrantFiled: September 10, 2012Date of Patent: May 20, 2014Assignee: KAI Pharmaceuticals, Inc.Inventors: Jonathan B. Rothbard, Paul A. Wender, Leo P. McGrane, Lalitha V. S. Sista, Thorsten A. Kirschberg
-
Publication number: 20140135267Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: Alcon Research, Ltd.Inventor: Jon E. Chatterton
-
Patent number: 8722012Abstract: The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer. The method includes administering an effective amount of perchlorate anion to the eyes of the patient.Type: GrantFiled: August 8, 2013Date of Patent: May 13, 2014Inventor: Kenneth Eli Morgenstern
-
Publication number: 20140127163Abstract: Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Shivalingappa Kottur Swamynathan, Sudha Swamynathan, Kristine-Ann Gallegos Buela, Robert Lee Hendricks
-
Publication number: 20140121161Abstract: The invention provides hydrogels and methods for their use in treating disorders of the retina such as age-related macular degeneration (AMD).Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Andrea S. Gobin, Tongalp H. Tezel
-
Publication number: 20140107041Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.Type: ApplicationFiled: September 5, 2013Publication date: April 17, 2014Applicant: DYAX CORP.Inventors: AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN NUNN, RADHAKRISHNA PILLAI, SYBILLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATTHEW A. VON WRONSKI
-
Publication number: 20140107037Abstract: The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine site partial agonist.Type: ApplicationFiled: April 27, 2012Publication date: April 17, 2014Inventor: Joseph Moskal
-
Publication number: 20140099343Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: ApplicationFiled: September 20, 2013Publication date: April 10, 2014Applicants: Schepens Eye Research Institute, The Regents of the University of CaliforniaInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8691760Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: GrantFiled: February 2, 2010Date of Patent: April 8, 2014Assignee: Ramot at Tel-Aviv UniversityInventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Publication number: 20140094419Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.Type: ApplicationFiled: October 18, 2013Publication date: April 3, 2014Applicant: Alcon Research Ltd.Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
-
Publication number: 20140087994Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: November 7, 2013Publication date: March 27, 2014Applicants: Universitaet Zuerich, POLYPHOR LTD.Inventors: Steven J. DEMARCO, Wim Vrijbloed, Ricardo Dias, John Anthony Robinson, Nityakalyani Srinivas, Frank Gombert, Daniel Obrecht
-
Publication number: 20140088015Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.Type: ApplicationFiled: April 26, 2013Publication date: March 27, 2014Inventors: Samuel B. Ho, Laurie L. Shekels
-
Publication number: 20140082769Abstract: The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial, fungal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.Type: ApplicationFiled: March 12, 2012Publication date: March 20, 2014Inventors: Joost Schymkowitz, Frederic Rousseau
-
Publication number: 20140080765Abstract: The present invention provides: a novel metalloprotein, i.e., selenium-lactoferrin; and a process for producing the metalloprotein. Selenium-lactoferrin according to the present invention can be produced suitably by adding a selenium salt to a solution containing lactoferrin and/or apolactoferrin and then subjecting the resultant mixed solution to dialysis or ultrafiltration. Selenium-lactoferrin according to the present invention has an excellent therapeutic effect on corneal and conjunctival diseases, and is suitable for mass production on an industrial scale.Type: ApplicationFiled: May 18, 2012Publication date: March 20, 2014Applicants: KOWA COMPANY, LTD., KEIO UNIVERSITYInventors: Akihiro Higuchi, Hiroyoshi Inoue, Kazuo Tsubota
-
Publication number: 20140073572Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.Type: ApplicationFiled: October 1, 2013Publication date: March 13, 2014Applicants: MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body CorporateInventors: Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
-
Publication number: 20140066384Abstract: Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.Type: ApplicationFiled: April 15, 2013Publication date: March 6, 2014Applicants: MedStar Health Research Institute, Inc., Georgetown UniversityInventors: Anton Wellstein, Marcel O. Schmidt, Stephan Zbinden, Mary Susan Burnett, Stephen E. Epstein
-
Publication number: 20140057833Abstract: Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.Type: ApplicationFiled: April 11, 2012Publication date: February 27, 2014Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laszlo Otvos, Eva Surmacz
-
Publication number: 20140051639Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.Type: ApplicationFiled: October 29, 2013Publication date: February 20, 2014Applicant: The Children's Hospital of PhiladelphiaInventor: Michael M. Grunstein